|Articles|February 8, 2022

ICD-10-CM Diagnosis Codes for 2022

Effective each year on October 1, additions, deletions, and updates to the ICD-10-CM code set are published. This year, no significant changes were made to Chapter 15, the obstetrics chapter. However, there are a few new codes that could affect the practice of maternal-fetal medicine.

View as PDF

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Subscribe Now!

Related Content

Zoliflodacin demonstrated non-inferiority in adults and adolescents with gonorrhea

ByMorgan Ebert, Managing Editor

December 11th 2025

FDA approves gepotidacin (Blujepa) oral therapy for uncomplicated urogenital gonorrhea

ByMorgan Ebert, Managing Editor

December 11th 2025

Early ultrasound linked to improved fetal anomaly detection

ByCeleste Krewson, Assistant Editor

December 11th 2025

Maternal GBS vaccine (GBS-AlpN) shows immunogenicity and acceptable safety in phase 2 trial

ByMorgan Ebert, Managing Editor

December 11th 2025

DARE to PLAY sildenafil cream becomes commercially available for women in select states

ByMorgan Ebert, Managing Editor

December 10th 2025

Latest CME

Multimedia

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Rachel N. Grisham, MD; Domenica Lorusso, MD, PhD

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Jill Alldredge, MD; Emely Alfaro, MS, RN, CNS, OCN

Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Emely Alfaro, MS, RN, CNS, OCN; Jill Alldredge, MD

Video

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Danielle Nance, MD; Kimberley Youkhana, MD

ICD-10-CM Diagnosis Codes for 2022

Newsletter

Related Content

Zoliflodacin demonstrated non-inferiority in adults and adolescents with gonorrhea

FDA approves gepotidacin (Blujepa) oral therapy for uncomplicated urogenital gonorrhea

Early ultrasound linked to improved fetal anomaly detection

Maternal GBS vaccine (GBS-AlpN) shows immunogenicity and acceptable safety in phase 2 trial

DARE to PLAY sildenafil cream becomes commercially available for women in select states

Latest CME

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Trending on Contemporary OB/GYN

DARE to PLAY sildenafil cream becomes commercially available for women in select states

FDA approves gepotidacin (Blujepa) oral therapy for uncomplicated urogenital gonorrhea

Early ultrasound linked to improved fetal anomaly detection

Maternal GBS vaccine (GBS-AlpN) shows immunogenicity and acceptable safety in phase 2 trial

Zoliflodacin demonstrated non-inferiority in adults and adolescents with gonorrhea